Merck & Co Inc
Stocks making the biggest moves midday: Novo Nordisk, Inspire Medical, Tesla, Tegna, Oscar Health and more
Check out the companies making the biggest moves midday: Novo Nordisk — The Danish pharmaceutical company’s trial for Alzheimer’s disease failed to meet its main goal of slowing the disease’s progression. Shares tumbled nearly 6%. Inspire Medical Systems — The maker of an obstructive sleep apnea treatment will benefit from Friday’s decision by the Centers […]
Read More
Stocks making the biggest moves premarket: Novo Nordisk, Tesla, Alphabet, Oscar Health & more
Check out the companies making the biggest moves in premarket trading: Novo Nordisk — Shares tumbled 10% after the Danish pharmaceutical company’s trial for Alzheimer’s disease failed to meet its main goal of slowing the disease’s progression. Tesla — CEO Elon Musk said on X that the company is close to finalizing its latest artificial-intelligence […]
Read More
We don’t have high hopes for this tech stock, but we’re thrilled with this bank
Two portfolio stocks are making news Monday — one in enterprise software and the other in banking. Earnings preview : Bank of America lowered its price target on Salesforce to $305 per share from $325 ahead of quarterly earnings next month. The analysts, who kept a buy rating on shares, cited cheaper multiples across software peers, […]
Read More
Stocks making the biggest premarket moves: Warner Bros. Discovery, Cidara Therapeutics, Avadel Pharmaceuticals and more
Check out the companies making headlines before the bell. Cidara Therapeutics — Shares of Cidara surged 103% after Merck agreed to buy the company for close to $9.2 billion in cash. Merck fell 1%. Avadel Pharmaceuticals — Danish drugmaker Lundbeck offered to acquire the pharmaceutical company for as much as $23 per share, topping biotech […]
Read More
Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics
Exterior view of the entrance to Merck headquarters on February 05, 2024 in Rahway, New Jersey. Spencer Platt | Getty Images Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention. Merck is looking to diversify its revenue beyond Keytruda […]
Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]
Read More
Stocks making the biggest moves premarket: Alphabet, Microsoft, Meta Platforms, Eli Lilly, Merck & more
Check out the companies making headlines before the bell: Alphabet — The search giant jumped more than 7% after strong results that were boosted by revenue from Google Cloud and YouTube advertising. Alphabet earned $3.10 per share, on an adjusted basis, more than the $2.33 per share expected by analysts polled by LSEG. Revenue of […]
Read More
Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
Merck on Thursday reported third-quarter earnings and revenue that topped estimates as it saw strong demand for its cancer immunotherapy Keytruda. The drugmaker also narrowed its full-year profit outlook to reflect lower estimated tariff costs, among other factors. Sales of Keytruda topped $8 billion for the first time in a quarter, rising 10% from the […]
Read More
Market moves after the Fed rate cut — plus, two price target hikes on big-name stocks
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: The S & P 500 flipped between positive and negative Wednesday afternoon after Federal Reserve Chairman Jerome Powell said a December interest rate cut was […]
Read More
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
The Eli Lilly & Co. logo at the company’s Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Ore Huiying | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future […]
Read More